Eradication of Residual Disease by Preemptive Immunointervention After Allogeneic Hematopoietic Stem Cells Transplantation in Chronic Lymphocytic Leukemia
Conditions
- Chronic Lymphocytic Leukemia
- Lymphocytic Lymphoma
Interventions
- DRUG: Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)
Sponsor
University Hospital, Clermont-Ferrand
Collaborators